$15,605.62 consulting Payment -- Pfizer Inc to Dr. Melissa Reed

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Pfizer Inc made a $15.6K consulting payment to Melissa Reed, a Oncology specialist in City, AL. Melissa Reed received a $15,605.62 consulting fee from Pfizer Inc. on February 15, 2025. The payment was for consulting services related to oncology. This record represents a single payment event from a major pharmaceutical company to a healthcare provider.

Patient Guidance: What This Payment Means for You

If you are a patient, this payment indicates your doctor may be involved in consulting with pharmaceutical companies to share their expertise. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Consulting fees are common in the pharmaceutical industry, especially for specialists like oncologists who provide valuable insights into treatment and drug development.

Regulatory Context: Sunshine Act Requirements

This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

• pharmaceutical-payments
• consulting-fees
• oncology
• pfizer
• physician-payments
• open-payments

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $15.6K payment for?

This was a consulting payment of $15.6K from Pfizer Inc to Melissa Reed, categorized as "Consulting Fee". The payment was reported under the Sunshine Act (CMS Open Payments).

Does Melissa Reed accept pharmaceutical money?

Yes, Melissa Reed received this $15.6K payment from Pfizer Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Melissa Reed's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $15.6K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Oncology?

To compare this payment against Oncology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Oncology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Melissa Reed's relationship with Pfizer Inc?

The payment amount is substantial for a single consulting engagement. This $15.6K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Oncology?

Pfizer Inc. is a large pharmaceutical company with a broad range of products.

What should patients do after learning about this payment?

If you are a patient, this payment indicates your doctor may be involved in consulting with pharmaceutical companies to share their expertise.

What else should I know about this consulting payment?

The payment date is in the future, suggesting it may be a pre-arranged agreement.

Related Reports

• View Dr. Melissa Reed's full payment report
• Pfizer Inc full spending report
• Browse all Oncology payments
• Browse all payments in Alabama
• Search for other payments